ANI Pharmaceuticals Inc. (NASDAQ:ANIP) fell 2% on Friday . The stock traded as low as $60.01 and last traded at $60.22, with a volume of 126,118 shares changing hands. The stock had previously closed at $61.42.

Several brokerages have weighed in on ANIP. Zacks Investment Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 6th. Guggenheim reaffirmed a “buy” rating and issued a $55.00 target price (up from $50.00) on shares of ANI Pharmaceuticals in a research report on Saturday, May 7th. Oppenheimer Holdings Inc. raised their target price on shares of ANI Pharmaceuticals from $65.00 to $71.00 and gave the stock an “outperform” rating in a research report on Friday, August 5th. Raymond James Financial Inc. initiated coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, June 22nd. They issued a “strong-buy” rating and a $68.00 target price for the company. Finally, Standpoint Research cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, May 24th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and three have given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $64.00.

The firm has a market capitalization of $689.23 million and a P/E ratio of 70.34. The stock has a 50-day moving average of $63.40 and a 200 day moving average of $49.30.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Thursday, August 4th. The specialty pharmaceutical company reported $1.11 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.34. During the same quarter in the prior year, the firm posted $0.55 EPS. The business earned $31.30 million during the quarter, compared to the consensus estimate of $27.63 million. The company’s revenue for the quarter was up 60.5% on a year-over-year basis. Equities research analysts anticipate that ANI Pharmaceuticals Inc. will post $4.12 earnings per share for the current year.

In other ANI Pharmaceuticals news, VP Robert W. Schrepfer sold 12,500 shares of the business’s stock in a transaction on Monday, August 8th. The shares were sold at an average price of $67.06, for a total transaction of $838,250.00. Following the transaction, the vice president now owns 17,362 shares in the company, valued at $1,164,295.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Arthur Przybyl sold 37,455 shares of the business’s stock in a transaction on Monday, August 22nd. The shares were sold at an average price of $66.97, for a total transaction of $2,508,361.35. Following the transaction, the insider now owns 200,788 shares in the company, valued at approximately $13,446,772.36. The disclosure for this sale can be found here.

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company’s focused areas of product development include anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.